Table 1.

Initial antibiotic treatment in end-stage liver disease before liver transplantation [9, 21–23]

Infection type	Community-acquired	Nosocomial
SBP SBE Spontaneous bacteremia	Cefotaxime or ceftriaxone	Broad-spectrum beta-lactam- or carbapenem-based therapy based on local antibiogram ± vancomycin (if high percentage of VSE/MRSA)
Urinary infections with sepsis	Cefotaxime or ceftriaxone	Broad-spectrum beta-lactam- or carbapenem-based therapy based on local antibiogram ± vancomycin (if high percentage of VSE/MRSA)
Pneumonia	Ceftriaxone + macrolide or respiratory fluoroquinolone (moxifloxacin or levofloxacin)	Broad-spectrum beta-lactam- or carbapenem-based therapy based on local antibiogram ± vancomycin (if high percentage of VSE/MRSA)
Cellulitis	Nonpurulent infection (necrotizing infection/cellulitis/erysipelas): Severe: rule out necrotizing process; empiric anti-MRSA agent +piperacillin/tazobactam Moderate: ceftriaxone or cefazolin Purulent cellulitis (furuncle/carbuncle/abscess): Irrigation and debridement Empiric: anti-MRSA agent

SBP, spontaneous bacterial peritonitis; SFP, spontaneous fungal peritonitis; MRSA, methicillin-resistant Staphylococcus aureus; commonly administered anti-MRSA agents: vancomycin, daptomycin, linezolid, ceftaroline